RAF modulators and methods of use

被引：1

作者：

Boyer, Stephen J. ^{[1
]}

机构：

[1] Bayer Pharmaceut Corp, West Haven, CT 06516 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2006年 / 16卷 / 07期

关键词：

A-RAF; B-RAF; C-RAF; RAF-1 kinase inhibitor;

D O I：

10.1517/13543776.16.7.1031

中图分类号：

R914 [药物化学];

学科分类号：

100701 [药物化学];

摘要：

Exelixis claims a series of RAF kinase inhibitors based on a 3-oxo-2,3-dihydro-1H-isoindol-1-yl core structure. Both the chemical matter and the biochemical target appear to be new for Exelixis, and many examples have IC50 values < 100 nM. These compounds are claimed to have the potential to treat diseases that are associated with uncontrolled, abnormal and/or unwanted cellular activities such as cancer.

引用

页码：1031 / 1036

页数：6

共 38 条

[1]

AMIRI A, 2006, P AM ASS CANC RES WA

[2]

Anand N., 2005, Patent No. [2005/117909, 2005117909]

[3]

ANAND NK, 2005, Patent No. 2005112932

[4]

[Anonymous], [No title captured], Patent No. 2005030140

[5]

Second nature: Biological functions of the raf-1 "kinase" [J].

Baccarini, M .

FEBS LETTERS, 2005, 579 (15) :3271-3277

[6]

Bannen L. C., 2004, [No title captured], Patent No. [WO 2004050681 A2, 2004050681]

[7]

Bannen L. C., 2006, PCT WO, Patent No. [2006/014325 A2, 2006014325]

[8]

Raf: A strategic target for therapeutic development against cancer [J].

Beeram, M ;

Patnaik, A ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6771-6790

[9]

Buchstaller H.-P., 2005, [No title captured], Patent No. [WO2005004863A1, 2005004863]

[10]

BUHR CA, 2003, Patent No. 2003093297

← 1 2 3 4 →